louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02445755: Transcutaneous Bilirubinometry in Neonates With the Bilicare System
Official title: Transcutaneous Bilirubinometry in Neonates With the Bilicare System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Transcutaneous Bilirubinometry
Keywords: Neonates
Bilicare System
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2015-05-15
Enrollment: 113
Sex: ALL
Minimum age (years): 35
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Up to 100 total participants will be enrolled by the study. Since the goal of the study is to ASSAY SAMPLE FROM BABIES WITH DIVERSE BILIRUBIN LEVELS, the study participants will be moderate premature and mature infants. In particular, the target population will be moderate premature infants at \>35 weeks postmenstrual age (PMA) and of term PMA.

Brief summary: The purpose of this study is to test the performance of a new transcutaneous ("measured through skin") bilirubin device (BiliCare™) to measure bilirubin levels. The investigators plan to evaluate the clinical performance of this device as a point of care test. If the investigators can validate the BiliCare™ with bilirubin from your baby's blood they could verify a non-invasive alternative for measuring bilirubin.


Eligibility criteria: Inclusion Criteria:

1. Parental informed consent
2. Male and female newborns with a GA ≥ 35 wks
3. Enrollment at age \> 6 hrs until neonatal discharge
4. Pre-phototherapy

Exclusion Criteria:

1. Infants requiring respiratory assistance (such as mechanical ventilation)
2. Severe or life-threatening congenital anomalies
3. Hematomas at the point of measurement on both ears
4. Neonates undergone blood transfusion

Primary outcomes:
measure: In This Study, the Investigators Plan to Test the Performance of a Novel Transcutaneous Device (BiliCareTM) to Screen for Bilirubin Levels at Postnatal Age of 12 to 48 Hours.
timeFrame: 12 to 48 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03566355: Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Official title: A Phase II Study of Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Keywords: Lung Metastasis, Curative Proton Beam Therapy
Lead sponsor: National Cancer Center, Korea
Sponsor class: OTHER_GOV
First posted: 2018-06-25
Enrollment: 36
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Proton alone therapy is performed

-\> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

Detailed description: This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the efficacy of curative proton therapy for pulmonary metastasis of colon cancer diagnosed histologically as adenocarcinoma.

Patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.

Eligibility criteria: Inclusion Criteria:

1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions..
2. If there is no other remote metastasis other than lung, or if there is, control is possible
3. If there are less than 2 lung metastatic lesions
4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.)

Exclusion Criteria:

1. Other histologic cancer other than adenocarcinoma of the colorectal
2. Colorectal cancer without primary lesion resection
3. If there is another remote metastasis and is not completely resected or regulated
4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis
5. Pregnancy and women under lactation

Primary outcomes:
measure: 3-year local control ratio of the treated lung area
timeFrame: up to 3 years
Secondary outcomes:
measure: 3-year survival rate of treated patients
timeFrame: documented data of death, up to 3 years
measure: 3-year disease-free survival rate of treated patients
timeFrame: documented date of progression or death, up to 3 years
Other outcomes:
Locations:
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center Korea
state: Gyeonggi-do
Study officials:
affiliation: National Cancer Center Korea(South Korea)
name: Dae Yong Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00434655: Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy
Official title: Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy: A Prospective Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Morbid Obesity
Keywords: Morbid obesity
Bariatric surgery
Obesity surgery
Gastric banding
Sleeve gastrectomy
Lead sponsor: North Texas Veterans Healthcare System
Sponsor class: FED
First posted: 2007-02-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * The investigators aim to determine the clinical and metabolic outcomes of two available bariatric restrictive procedures: laparoscopic adjustable gastric banding (LAP-BAND) and laparoscopic sleeve gastrectomy for the treatment of morbid obesity (BMI \> 35 with comorbidities or BMI \> 40) in VETERANS.
* The investigators hypothesize that the short and long term outcomes between laparoscopic adjustable gastric banding (LAP-BAND) and sleeve gastrectomy are similar in VETERANS.

Detailed description: This is a bariatric surgery Phase 3 prospective trial.

Eligibility criteria: Inclusion Criteria:

* Morbidly obese VETERANS ONLY (BMI\>35 with comorbidities or BMI \> 40)
* Age \> 18 y/o

Exclusion Criteria:

* Pregnancy
* Severe uncontrolled medical or psychiatric conditions
* Previous bariatric surgery
* Multiple previous abdominal surgeries

Primary outcomes:
measure: Short and long term clinical outcomes
timeFrame: 5 years
Secondary outcomes:
measure: Metabolic outcomes
timeFrame: 5 years
measure: Esophago-gastric physiology
timeFrame: 2 years
measure: Hormonal physiology
timeFrame: 5 years
measure: Procedure costs
timeFrame: 5 years
Other outcomes:
Locations:
city: Dallas
country: United States
facility: VA North Texas
state: Texas
Study officials:
affiliation: VA North Texas
name: Esteban Varela, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00676455: Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions
Official title: Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Metastatic Cancer
Keywords: CT Software
MeVis™
Metastatic pulmonary and hepatic lesion growth
Lead sponsor: Lahey Clinic
Sponsor class: OTHER
First posted: 2008-05-13
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects to be recruited from the practice of the Oncology Department. All subjects with hepatic or pulmonary metastatic lesions will be offered the opportunity to participate

Brief summary: The purpose of this study is to evaluate the ability of a new type of CT computer program(MeVis™)to accurately analyze and measure the size and changes in metastatic Liver and Lung tumors. This study will evaluate the data from current CT evaluation methods using the MeVis™ 3-D software.

Detailed description: This is a Pilot Study that will evaluate if metastatic liver and lung tumor measurements made by the MeVis™ software program can provide more accurate information about the size and changes of the tumor compared to the current evaluation method, RECIST(Response Evaluation In Solid Tumors). This study will also collect information about the kind of treatment each subject receives.

Subjects will receive standard of care surveillance CT examinations(a baseline to document tumor size and interval CT exams as indicated by the Oncology Department Protocols); the tumor will be measured according to the current standard-RECIST by Radiology personnel not involved in the study. The CT data will then be analyzed by investigators using the MeVis™ software.

Eligibility criteria: Inclusion Criteria:

* Subjects with cancer metastatic to either the liver or lungs
* Subjects Scheduled for regular CT surveillance examinations
* Subjects with life expectancy of at least 6 months

Exclusion Criteria:

* Age \<18 years
* No written informed consent

Primary outcomes:
measure: This Study Assessed the Ability of MeVis™ Volumetry Software to Reproducibly Measure the Changes in Metastatic Hepatic and Pulmonary Lesions
timeFrame: As long as treatment is being assessed by CT examinations
Secondary outcomes:
measure: Tumor Size Will be Measured by CT (by the MeVis Volumetry Software and Correlated With On-going Treatment Plan.
timeFrame: As long as treatment is being assessed by CT examinations
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Lahey Clinic, Inc.
state: Massachusetts
Study officials:
affiliation: Lahey Clinic, Inc.
name: Christoph Wald, M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06785155: AI Chatbot-Based Learning on Dry Eye and Eye Strain Knowledge
Official title: AI Chatbot-Based Learning on Dry Eye and Eye Strain Knowledge Among Nursing Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health Behaviors
Artificial Intelligence (AI)
Chatbot
Dry Eye
Eye Strain
Lead sponsor: Gaziantep Islam Science and Technology University
Sponsor class: OTHER
First posted: 2025-01-21
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this project is to evaluate the effectiveness of using chatbots for patient education about dry eye disease. The study will examine how the chatbot affects patients' levels of information, managing symptoms, and overall satisfaction.


Eligibility criteria: Inclusion Criteria:

* to be actively enrolled in the nursing program
* to demonstrate baseline digital literacy.

Exclusion Criteria:

* diagnosed visual impairments,
* those with prior specialized ophthalmological training,
* individuals with limited digital technology proficiency

Primary outcomes:
measure: Dry Eye and eye strain knowledge questionnaire
timeFrame: From enrollment to the end of training at 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kilis
country: Turkey
facility: Deparment of Nursing, Kilis 7 Aralık University
state: Center
Study officials:
References:
Clinical trial NCT01438255: Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: Handok Inc.
Sponsor class: INDUSTRY
First posted: 2011-09-22
Enrollment: 274
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: outpatients

Brief summary: This is a prospective, non-comparative, open, observational study.


Eligibility criteria: Inclusion Criteria:

* Children who is prescribed with ciclesonide for asthma

Exclusion Criteria:

* Subjects with contraindications to ciclesonide use
* Subjects with clinically relevant concomitant disease that could compromise the patient's safety should not be included in this study.

Primary outcomes:
measure: Asthma control day
timeFrame: 12weeks
Secondary outcomes:
measure: Morning peak expiratory flow
timeFrame: 12weeks
measure: asthma exacerbation
timeFrame: 12weeks
measure: The number of Reliever use
timeFrame: 12weeks
measure: Asthma symptom score
timeFrame: 12weeks
measure: Number of Participants with Adverse Events
timeFrame: 12weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Handok Pharmaceuticals
Study officials:
References:
Clinical trial NCT04959955: Project to Improve the Diagnosis and Treatment Ability of Adult Severe Community Acquired Lower Respiratory Tract Infection
Official title: Project to Improve the Diagnosis and Treatment Ability of Adult Severe Community Acquired Lower Respiratory Tract Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: CAP
COPD Exacerbation
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
Collaborators: name: First Hospital of China Medical University
First posted: 2021-07-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult hospitalized cases of SCAP and acute exacerbation of COPD were collected from 12 medical institutions in 10 cities in China within 2 years.

Brief summary: 1. Objective to understand the proportion of atypical pathogens in the pathogens of SCAP and AECOPD in urban hospitals in China.
2. Objective to investigate the antimicrobial resistance of atypical pathogens in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and SCAP in urban hospitals.
3. Objective to master the important clinical characteristics of patients with acute exacerbation of SCAP and COPD caused by atypical pathogens and mixed infection in urban hospitals in China, and to put forward the experience judgment index.
4. Objective to evaluate the advantages of various diagnostic methods for atypical pathogens causing lower respiratory tract infection.
5. It is suggested that the current empirical treatment of SCAP and severe COPD in China should be improved.


Eligibility criteria: Inclusion Criteria:

* SCAP
* AECOPD

Exclusion Criteria:

* Pregnant or lactating women.

  * Patients with bronchiectasis.

    * Patients with active pulmonary tuberculosis.

      * Aspiration pneumonia or obstructive pneumonia.

        * Two weeks before the onset of hospital treatment history, this infection can not be excluded from hospital acquired infection.

          * HIV positive patients (but HIV testing is not required).

            * Patients who are unable and / or unable to understand and / or implement the investigation protocol.

Primary outcomes:
measure: Incidence of atypical pathogens and mixed infections
timeFrame: 2year Incidence
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04897555: LLLT for Alopecia of the Eyebrow in Women
Official title: Evaluation of Low Level Light Therapy (LLLT) as a Primary Therapy for Non-Specific Alopecia of the Eyebrow in Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alopecia
Lead sponsor: Freedom Laser, Inc.
Sponsor class: INDUSTRY
First posted: 2021-05-21
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system that will emit light on the hair growth cells within and around the hair follicle. When these cells do not function properly, one may experience common problems such as baldness and thinning or brittle hair. The application of a special category of low-level light to be studied in the project may cause an increase in essential nutrients to the damaged hair follicles and skin cells, leading to a reduction in hair loss and in some cases, possibly leading to re-growth.

Detailed description: This study on LLLT aims to define the safety and physiologic effects that occur when the human hair follicle and surrounding tissue structures are exposed to this type of radiation. Thus far, all reports on the efficacy of laser light and LED light in this area, have been, in large part, unsupported by multi-center, randomized, double blind, controlled studies. To properly identify the effects in human subjects, exposure to LLLT is not sufficient. The analysis of the non-radiated and radiated tissues is required to elucidate the tissue response and efficacy of the laser therapy. The theory that is widely accepted is that the mitochondria are the powerhouse of the stem cells that cause hair growth. The LLLT "turns on" the nutrient pump process that energizes the mitochondria, which leads to an increase in ATP and subsequent reversal of hair follicles from the dormant stage of growth called telogen, to the active growth stage called anagen.

Eligibility criteria: Inclusion Criteria:

* Female subjects experiencing any type of non-traumatic eyebrow hair loss.
* Apparent good health.

Exclusion Criteria:

* Previous involvement in other eyebrow hair studies.
* Use of any hair growth agent within the last 4 weeks.
* Evidence of any current viral, fungal or bacterial infection.

Primary outcomes:
measure: Change in number of terminal hairs
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mendham
country: United States
facility: NST Consultants, Inc.
state: New Jersey
city: Great Neck
country: United States
facility: Bodian Dermatology
state: New York
Study officials:
affiliation: Bodian Dermatology Group
name: Adam Bodian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05738655: Effectiveness of Pumpkin Seed Extract on Improving Blood Sugar Level in Subhealth Subjects
Official title: Effectiveness of Pumpkin Seed Extract on Improving Blood Sugar Level in Subhealth Subjects
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diabetes
Metabolic Disease
Lead sponsor: Greenyn Biotechnology Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Taipei Medical University
First posted: 2023-02-22
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: PREVENTION

Brief summary: This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract on blood sugar management in subhealth people.


Eligibility criteria: Inclusion Criteria:

* Fasting blood sugar levels from 100 to 125 mg/dL
* Glycated hemoglobin levels from 5.7 to 6.4%
* 2-hour OGTT levels from 140 to 199 mg/dL

Exclusion Criteria:

* Pregnant women or preparing for pregnancy.
* Lactating women.
* Women gave birth 6 months before the study.
* Poor kindy funciton
* Severe cardiovascular or other chronic diseases
* Patients with type I or II diabetes
* Poor compliance
* Alcohol abuser
* Using anti-diabetic or weight managent supplements
* Blood transfusion three months before the study
* Pumpkin seed allergy

Primary outcomes:
measure: Biochemical analysis
timeFrame: Baseline up to 12 weeks
measure: Biochemical analysis
timeFrame: Baseline up to 12 weeks
measure: Biochemical analysis
timeFrame: Baseline up to 12 weeks
measure: Biochemical analysis
timeFrame: Baseline up to 12 weeks
measure: Hormone analysis
timeFrame: Baseline up to 12 weeks
measure: Hormone analysis
timeFrame: Baseline up to 12 weeks
measure: Hormone analysis
timeFrame: Baseline up to 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: WanFang Hospital
Study officials:
affiliation: WanFang Hospital
name: Ming-Shun Wu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03051555: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Official title: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lymphoma, Extranodal NK-T-Cell
Keywords: Lymphoma, Extranodal NK-T-Cell
Positron-Emission Tomography
Prognosis
Lead sponsor: Peking University Cancer Hospital & Institute
Sponsor class: OTHER
Collaborators: name: Beijing Municipal Administration of Hospitals
First posted: 2017-02-13
Enrollment: 60
Sex: ALL
Minimum age (years): 12
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression

Detailed description: In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/ CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in NK/T-cell lymphoma.

Eligibility criteria: Inclusion Criteria:

* newly diagnosed NK/T-cell lymphoma
* treated using an anthracycline-containing regimen
* minimal follow-up at 6 months after the completion of first-line treatment
* complete medical history and clinicopathological data

Exclusion Criteria:

* secondary malignant disease
* serious infection or inflammation (e.g., HIV)
* primary central nervous system lymphoma
* hepatic or renal dysfunction.

Primary outcomes:
measure: 3 year progression-free survival
timeFrame: up to 3 years after initial diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital
state: Beijing
Study officials:
References: